Saturday, 26 September 2020

SunGen, Camber launches generic Bentyl Injection in US market

27 January 2020 | News

Dicyclomine is used to treat with severe irritable bowel syndrome and bowel spasms

image credit:

image credit:

US based SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products. SunGen has business partnerships with many North American, European and Asian-based generic pharmaceutical companies to develop, manufacture, and sell several pharmaceutical products around the world.

SunGen Pharma has announced the U.S. launch and commercial shipment of generic version of Bentyl® (Dicyclomine) Injection, in collaboration with Camber Pharmaceuticals, a part of the Hetero Group of companies in Hyderabad, India which will be SunGen's distribution and marketing partner.

Dicyclomine Hydrochloride Injection USP, 20 mg/2 mL (10 mg/mL) is a sterile injectable in a 2ml-vial. Dicyclomine is used to treat with severe irritable bowel syndrome and bowel spasms. Dicyclomine injection had total U.S. sales of $17 million for year of 2018 according to IQVIA.

Isaac Liu, Ph.D., Co-CEO of SunGen, stated, "We are proud to add Dicyclomine to our growing portfolio of more than 40 specialty products. The launch of Dicyclomine Injection demonstrates our strong development and partnership capabilities. SunGen continues to expand its product development portfolio and has secured nine ANDA approvals and has an additional six filed with the FDA. We have also acquired or exclusively in licensed five ANDAs. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world."

Arun Nataraj, Ph.D., Camber's Vice-President of Business Development, commented, "Camber has had a remarkable track record of launching oral solid and oral liquid ANDA products successfully in the US marketplace. Now with the launch of our first injectable product, Camber is transitioning into the more complex generics space. We plan to launch more injectable products in 2020 as part of our growth and product diversification strategy."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account